Pharma services has been a consensus-bullish sector for the last three years, and much of that consensus is well-founded. Demand for sterile fill-finish, peptide synthesis, ADC manufacturing, and specialty CRO services is real and durable. Capital remains available. Multiples have held up better than most healthcare sub-sectors through the most recent rate cycle. Several developments within that bullish picture, however, warrant closer attention, particularly as they begin to differentiate winners from average performers. None of these themes overturns the broader sector thesis. All are increasingly relevant for founders preparing for a transaction and sponsors building positions in the space. Here are the three themes likely to matter most over the next 24 months.
Read the full article: Three Themes Reshaping Pharma Services M&A //
Source: https://skytalegroup.com/blog/three-themes-reshaping-pharma-services-ma/